ArticleThe Clinical Benefits of the Leukoreduction of Blood ProductsBlajchman, M A. MD, FRCP(C)Author Information From McMaster University, Departments of Pathology and Medicine and Canadian Blood Services; Hamilton, Ontario, CANADA (M.B.) Received for publication November 18, 2005. Accepted for publication November 28, 2005. Address for reprints: Dr. M. A. Blajchman, Departments of Pathology and Medicine, McMaster University Medical Centre, 1200 Main Street West, HSC 2N34, Hamilton, Ontario, Canada, L8N 3Z5; email: [email protected] The Journal of Trauma: Injury, Infection, and Critical Care: June 2006 - Volume 60 - Issue 6 - p S83-S90 doi: 10.1097/01.ta.0000199537.09201.7b Buy Metrics Abstract Many adverse events associated with the transfusion of allogeneic blood products have been shown to be related to the presence of allogeneic leukocytes in the blood product transfused. Until recently little attention has been paid to the leukocytes present in various blood components, however, over the past two decades it has been shown that the removal of such “passenger” leukocytes is associated with improved clinical outcomes. These include: the reduction in the incidence and severity of febrile transfusion reactions; reducing the CMV transfusion transmission risk; reducing the risk of alloimmune platelet refractoriness; the possible avoidance of vCJD transmission; as well as reducing the risk of mortality and organ dysfunction in cardiac surgery patients, and possibly in other categories of patients. © 2006 Lippincott Williams & Wilkins, Inc.